RT Journal Article
SR Electronic
T1 Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
JF Science
JO Science
FD American Association for the Advancement of Science
SP 126
OP 129
DO 10.1126/science.1129003
VO 314
IS 5796
A1 Morgan, Richard A.
A1 Dudley, Mark E.
A1 Wunderlich, John R.
A1 Hughes, Marybeth S.
A1 Yang, James C.
A1 Sherry, Richard M.
A1 Royal, Richard E.
A1 Topalian, Suzanne L.
A1 Kammula, Udai S.
A1 Restifo, Nicholas P.
A1 Zheng, Zhili
A1 Nahvi, Azam
A1 de Vries, Christiaan R.
A1 Rogers-Freezer, Linda J.
A1 Mavroukakis, Sharon A.
A1 Rosenberg, Steven A.
YR 2006
UL http://science.sciencemag.org/content/314/5796/126.abstract
AB Through the adoptive transfer of lymphocytes after host immunodepletion, it is possible to mediate objective cancer regression in human patients with metastatic melanoma. However, the generation of tumor-specific T cells in this mode of immunotherapy is often limiting. Here we report the ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood by using a retrovirus that encodes a T cell receptor. Adoptive transfer of these transduced cells in 15 patients resulted in durable engraftment at levels exceeding 10% of peripheral blood lymphocytes for at least 2 months after the infusion. We observed high sustained levels of circulating, engineered cells at 1 year after infusion in two patients who both demonstrated objective regression of metastatic melanoma lesions. This study suggests the therapeutic potential of genetically engineered cells for the biologic therapy of cancer.